Methods and Compositions for the Inhibition of Stat5 in Prostate Cancer Cells
Efficient therapy to treat hormone resistant tumorSelective inhibition of prostate cancer cellsProvides a specific drug target against an extremely difficult-to-treat cancerExtensive cancerous cell death upon administration
The central problem in clinical management of prostate cancer is the development of hormone-refractory and metastatic disease. Androgen deprivation therapy only provides a temporary inhibition of the cancer growth before the hormone-refractory form of prostate cancer develops. Moreover, no effective pharmacologic treatments exist for elimination of residual cancer cells after prostate cancer surgery. The present invention identifies a new therapeutic target, namely, Signal Transducer and Activator of Transcription (Stat5a/b) that has potential for developing better therapeutic interventions for primary and advanced prostate cancer. It also describes various STAT5 inhibitors and an assay for diagnosing prostate cancer due to activated STAT5 in tissue samples.
美國
